Literature DB >> 22803022

A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.

Emma Allen-Vercoe1, Gregor Reid, Norman Viner, Gregory B Gloor, Susy Hota, Peter Kim, Christine Lee, Kieran O'Doherty, Stephen J Vanner, J Scott Weese, Elaine O Petrof.   

Abstract

A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.

Entities:  

Mesh:

Year:  2012        PMID: 22803022      PMCID: PMC3395448          DOI: 10.1155/2012/213828

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  34 in total

Review 1.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

2.  Effect of bowel preparation and colonoscopy on post-procedure intestinal microbiota composition.

Authors:  V Mai; B Greenwald; J Glenn Morris; J-P Raufman; O C Stine
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

3.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

Authors:  Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

4.  The appendix may protect against Clostridium difficile recurrence.

Authors:  Gene Y Im; Rani J Modayil; Cheng T Lin; Steven J Geier; Douglas S Katz; Martin Feuerman; James H Grendell
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-13       Impact factor: 11.382

5.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection.

Authors:  Matthew J Hamilton; Alexa R Weingarden; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Gastroenterol       Date:  2012-01-31       Impact factor: 10.864

7.  Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans.

Authors:  Brian D Muegge; Justin Kuczynski; Dan Knights; Jose C Clemente; Antonio González; Luigi Fontana; Bernard Henrissat; Rob Knight; Jeffrey I Gordon
Journal:  Science       Date:  2011-05-20       Impact factor: 47.728

8.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

9.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.

Authors:  Denise Gravel; Mark Miller; Andrew Simor; Geoffrey Taylor; Michael Gardam; Allison McGeer; James Hutchinson; Dorothy Moore; Sharon Kelly; David Boyd; Michael Mulvey
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

10.  Microbiome profiling by illumina sequencing of combinatorial sequence-tagged PCR products.

Authors:  Gregory B Gloor; Ruben Hummelen; Jean M Macklaim; Russell J Dickson; Andrew D Fernandes; Roderick MacPhee; Gregor Reid
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

View more
  29 in total

Review 1.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

2.  Infection: treating recurrent C. difficile infection-the challenge continues.

Authors:  Christina M Surawicz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-04       Impact factor: 46.802

3.  The art of targeting gut microbiota for tackling human obesity.

Authors:  Marisol Aguirre; Koen Venema
Journal:  Genes Nutr       Date:  2015-05-20       Impact factor: 5.523

4.  The microbiome: what it means for medicine.

Authors:  Emma Allen-Vercoe; Elaine O Petrof
Journal:  Br J Gen Pract       Date:  2014-03       Impact factor: 5.386

Review 5.  The intestinal microbiome in type 1 diabetes.

Authors:  J L Dunne; E W Triplett; D Gevers; R Xavier; R Insel; J Danska; M A Atkinson
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

6.  Asymptomatic gastric bacterial overgrowth after bariatric surgery: are long-term metabolic consequences possible?

Authors:  Robson K Ishida; Joel Faintuch; Adriana Safatle Ribeiro; Ulysses Ribeiro; Ivan Cecconello
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

7.  Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy.

Authors:  Paul Moayyedi; John K Marshall; Yuhong Yuan; Richard Hunt
Journal:  Can J Gastroenterol Hepatol       Date:  2014-02

Review 8.  From stool transplants to next-generation microbiota therapeutics.

Authors:  Elaine O Petrof; Alexander Khoruts
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

Review 9.  Type 1 diabetes and gut microbiota: Friend or foe?

Authors:  Changyun Hu; F Susan Wong; Li Wen
Journal:  Pharmacol Res       Date:  2015-03-05       Impact factor: 7.658

Review 10.  The role of the microbiome in rheumatic diseases.

Authors:  Nigel Yeoh; Jeremy P Burton; Praema Suppiah; Gregor Reid; Simon Stebbings
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.